噻克沙星 | 34976-39-1

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 喹诺酮类药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 噻克沙星
• 中文别名: 替氧沙星
• 英文名称: Tioxacin
• 英文别名: 6-ethyl-3-methyl-2,9-dioxo-2,3,6,9-tetrahydro-thiazolo[5,4-f]quinoline-8-carboxylic acid；6-ethyl-3-methyl-2,9-dioxo-[1,3]thiazolo[5,4-f]quinoline-8-carboxylic acid
• CAS: 34976-39-1
• 化学式: C₁₄H₁₂N₂O₄S
• 分子量: 304.326
• InChiKey: VUUPJGYIOAVFAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-amino-3-methyl-2(3H)-benzothiazolone 在 盐酸 、 溶剂黄146 作用下， 反应 3.0h， 生成 噻克沙星
  参考文献：
  名称：

  Synthetic chemotherapeutic agents. IV. Synthesis of 3-substituted thiazolo(5,4-f)quinoline derivatives.

  摘要：

  研究并证明了通过噻唰盐合成3,6-二取代-2,9-二氧-2,3,6,9-四氢噻唑并[5,4-f]喹啉-8-羧酸的方法是切实可行的。噻唑盐与各种亲核试剂的反应得到了几种新衍生物。还进行了苯并噻唑-2-酮和苯并噻唑-2-硫酮衍生物的Gould-Jacobs反应。

  DOI：

  10.1248/cpb.24.1050

文献信息

• Synthetic chemotherapeutic agents. III. Synthesis of 3-substituted thiazolo(5,4-f)quinoline derivatives. (1).
  作者：SHIZUO KADOYA、NORIO SUZUKI、ISAO TAKAMURA、RENZO DOHMORI

  DOI：10.1248/cpb.24.147

  日期：——

  For the search of the more active antimicrobial compounds than the 2, 6-disubstituted derivatives, 3, 6-disubstituted 2, 3, 6, 9-tetrahydro-2, 9-dioxothiazolo [5, 4-f] quinoline-8-carboxylic acid (1, 3, 7, 8, 11, 20, 21, and 22) were synthesized from the 2-oxo-6-substituted thiazolo [5, 4-f] quinoline derivatives (2, 17, or 18). Thermal rearrangement of the 2-methylthio derivative (23) gave the 2-thioxo-3-methyl derivative (24), which was converted into the 2-oxo-3-methyl derivative (26) by reaction with mercuric acetate. The 2-ethoxy derivative (27) was also thermally rearranged to give the 2-oxo-3-ethyl derivative (8b). The 3, 6-disubstituted compounds obtained in this work showed the stronger activities against gram-negative and gram-positive bacteria in vitro than nalidixic acid and the 2, 6-disubstituted derivatives prepared in the previous work. 6-Ethyl-2, 3, 6, 9-tetrahydro-3-methyl-9-oxothiazolo [5, 4-f] quinoline-8-carboxylic acid (8a) exhibited the strongest activities among these compounds against many gram-negative bacteria including E. coli resistant to nalidixic acid and Ps. aeruginosa, and against some gram-positive bacteria.

  为了寻找比2,6-取代衍生物更活跃的抗微生物化合物，合成了3,6-取代的2,3,6,9-四氢-2,9-二氧噻唑[5,4-f]喹啉-8-羧酸（1、3、7、8、11、20、21和22），这些化合物是从2-氧-6-取代噻唑[5,4-f]喹啉衍生物（2、17或18）合成的。2-甲基硫衍生物（23）的热重排反应生成了2-硫氧-3-甲基衍生物（24），该衍生物与醋酸汞反应转化为2-氧-3-甲基衍生物（26）。2-醇乙氧基衍生物（27）也经过热重排生成了2-氧-3-乙基衍生物（8b）。本研究中获得的3,6-取代化合物在体外对革兰阴性菌和革兰阳性菌的活性较之前工作中制备的氟喹诺酮酸和2,6-取代衍生物更强。6-乙基-2,3,6,9-四氢-3-甲基-9-氧噻唑[5,4-f]喹啉-8-羧酸（8a）在这些化合物中对包括对氟喹诺酮酸耐药的大肠杆菌和铜绿假单胞菌在内的多种革兰阴性菌，以及对一些革兰阳性菌表现出最强的活性。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13
• CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION
  申请人：STI Pharma, LLC

  公开号：EP2717860A1

  公开（公告）日：2014-04-16